Bacterial Infections and Mycoses

318 trials 133 recruiting

Filter these 318 trials by phase, country and sponsor.

Open in Search →

Study of the Safety and lmmunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, T… Ended

2024-512271-13-00 Pneumococcal immunisation 5 2025-05-08
EMAPALUMAB TREATMENT FOR ANTICIPATED CLINICAL BENEFIT IN SEPSIS DRIVEN BY THE INTERFERON-GAMMA ENDOTYPE (THE EMBRACE TRIAL) Ended

2024-515255-38-00 SEPSIS 4 2025-03-12
Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers,… Ended

2023-510465-10-00 Meningococcal immunization 4 2025-03-10
A follow-up trial of GBS NN/NN2 vaccine in healthy pregnant women Ended

2024-516364-28-00 Prevention of Group B streptoccoccus infection 10 2025-03-07
Phase I study to evaluate safety and immunogenicity of V-212 in healthy adult volunteers. Ended

2024-516008-41-00 Healthy Volunteers 1 2025-01-29
A phase 4, randomised vaccination study in healthy adults to investigate the effects of acellular pertussis vaccine on colonisation with Bor… Ended

2023-508416-35-00 Pertussis or 'whooping cough' 6 2024-10-16
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize… Ended

2023-507527-28-00 Recurrent vulvovaginal candidiasis 7 2024-09-16
Men4age study Ended

2024-513640-29-00 Invasive meningococcal disease, sepsis, meningitis 6 2024-05-13
Clinical trial to evaluate the safety and efficacy of a 7-day versus 14-day treatment for enterococcal infections. Ended

2023-508456-18-00 Uncomplicated bacteremia caused by E. faecalis or E. fa 6 2024-04-29
Meningococcal B vaccine in patients with asplenia Ended

2023-508192-36-00 Splenectomy 4 2024-03-05
A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE IN… Ended

2022-502962-26-00 Severe infections 5 2023-09-14
The effect of systemic antibiotics on post-surgical complications and patient-centered outcomes in patients undergoing implant surgery with … Ended

2024-511366-36-00 implant surgery with guided bone regeneration and simul 6 2022-12-29
SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies amo… Ended

2024-513649-35-00 Asplenia 5 2022-09-15
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Boo… Ended

2023-510145-25-00 Meningococcal infection 5 2022-08-23
Efficacy of dalbavancin in osteoarticular infections associated with hip, knee and shoulder prostheses PRO-DALBA Ended

2024-518183-12-00 prosthetic joint infections 10 2022-03-07
A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different… Ended

2023-504301-37-00 Meningitis, Meningococcal 4 2022-03-03
Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended

2024-515398-90-01 Staphylococcus aureus bacteremia 5 2020-08-17
A phase II/III multi-centre, open-label, parallel group study to prove the non-inferiority of safety and efficacy of Metronidazole/Neomycin … Halted

2024-518862-28-00 female patients with bacterial vaginosis (BV), respecti 10 2024-11-19
Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted

2022-502049-91-00 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP) 4 2023-09-26
A study to investigate pharmacokinetics, safety, and tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 ho… Halted

2024-518003-22-00 Complicated urinary tract infections including acute py 4 2023-01-20
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarith… Ended

2024-520153-21-00 Infectious diseases 2 2026-01-29
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg… Ended

2025-522562-70-00 infection 2 2025-09-08
A Phase 3 study to assess the immune response and safety of rMenB+OMV NZ in primed healthy participants (10 to 20 years old) Ended

2024-519549-31-00 Invasive meningococcal disease (IMD) 5 2025-09-05
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid f… Ended

2025-521718-24-00 infections 2 2025-07-28